N2,3,5,4'- tetrahydroxystilbene 2-o-beta-d-glucoside and copper compounds for use in melanin proliferation, grey hair pigmentation stimulation and Anti-dandruff therapy

Abstract

The invention relates to a composition comprising 2,3,5,4'- Tetrahydroxystilbene 2-O-β-D-glucoside and at least one compound comprising copper. Said composition id for medical and non-medical use, including for preventing and / or reversing hair greying and / or dandruff in a subject.

Description

[0001] SkyLab AG

[0002] 24.11.2025 / TW

[0003] N2, 3, 5, 4 ’ - TETRAHYDROXYSTILBENE 2-O-B-D-GLUCOSIDE AND COPPER COMPOUNDS FOR MELANIN PROLIFERATION, GREY HAIR PIGMENTATION STIMULATION AND ANTI -DANDRUFF THERAPY

[0004] FIELD OF THE INVENTION

[0005] The present invention pertains to the application of 2, 3, 5, 4 ' -Tetrahydroxystilbene 2-O-β-D-Glucoside and its combination with copper compounds to induce melanin synthesis in humans. The invention includes the use of these agents to prevent or reverse hair graying and as an anti-dandruff treatment. This invention falls within the fields of cosmetic and dermatological therapies and is intended for application in hair and scalp care products. Both 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-Glucoside and its combinations with copper compounds demonstrate stability and are fully compatible for incorporation into cosmetic and pharmaceutical formulations.

[0006] BACKGROUND OF THE INVENTION

[0007] The process of graying, or achromotrichia, is a natural aspect of the body' s aging mechanism. Globally, 6-23% of individuals exhibit up to 50% gray hair by the age of 50

[0001] . The depigmentation of hair typically initiates between the ages of 30 and 40 in individuals of European descent, around 40 in Asians, and between 40 and 50 in Africans [2-4 ]. Early-onset graying is defined as onset before 20 years in Caucasians, before 25 in Asians, and before 30 in Africans [4, 5].

[0008] In men, gray hair commonly begins at the temples and sideburns, later appearing on the crown and back of the head. In women, graying generally starts at the hairline, progressively extending towards the crown. While the onset age of gray hair is genetically influenced, early graying does not necessarily correlate with accelerated progression

[0006] .

[0009] Certain reversible factors contribute to premature graying, such as nutrient deficiencies. Deficiencies in vitamin B12, iron, and copper, along with severe protein insufficiency, are linked to hypopigmentation of hair [3, 7, 8 ]. Risk factors include vegetarian diets and atopic conditions

[0009] .

[0010] The human hair shaft comprises two main concentric regions: the inner cortex and the surrounding outer cuticle. Some hair shafts also contain a central medulla

[0002] . Histologically, five to six distinct subpopulations of melanocytes have been identified. Melanogenically active melanocytes are located at the hair exit point on the scalp, within the sebaceous gland, and around the dermal papilla within the hair bulb. Additionally, undifferentiated, inactive melanocytes are found in the upper hair follicle near the arrector pili muscle attachment point, along the outer root sheath of the follicle, and within the hair bulb matrix

[0010] . Active melanocytes synthesize and transfer melanin to cortical keratinocytes in the hair shaft; a minor portion of melanin is transported to the medulla, with even less reaching the cuticle

[0004] . The role of inactive melanocytes remains poorly understood, although they are believed to serve as a stem cell reservoir, capable of differentiating into melanin-producing cells in response to skin injury [2, 4 ].

[0011] Hair melanogenesis is closely linked to the stages of the hair growth cycle. Hair is actively pigmented during the anagen phase (growth phase) but not in the catagen (resting phase) or telogen (shedding phase) stages [3, 4 ]. In humans, anagen generally lasts around 3.5 years, requiring a sustained population of follicular melanocytes capable of producing significant amounts of melanin

[0011] . Follicular melanocytes, charac- terized by a larger Golgi apparatus and rough endoplasmic reticulum, are larger than epidermal melanocytes, facilitating the formation of larger melanosomes

[0012] . Follicular melanin also degrades more slowly than epidermal melanin, resulting in consistent pigmentation along the distal and proximal ends of the hair shaft

[0010] . The specific hair color is determined by the type of melanin pigment produced by follicular melanocytes, such as the black-brown eumelanin or the red-yellow pheomelanin [3].

[0012] A variety of factors stimulate melanogenesis at the follicular level, including melanocyte-stimulating hormone (MSH), adrenocorticotropic hormone (ACTH), endothelin-1, prostaglandins, leukotrienes, neutrophils, fibroblast growth factor, nitric oxide, and catecholamines [5]. Inhibitors of melanogenesis include sphingolipids, bone morphogenetic protein 4, and autoimmune processes, such as those observed in vitiligo and alopecia areata [2, 3, 10, 13]. Certain compounds or medical conditions can influence the production of melanogenic factors, thereby altering hair pigmentation. Conditions sometimes associated with hair darkening include Addison' s disease, neurodermatitis, late-onset porphyria cutanea, and inflammatory scalp diseases [2, 14-16]. Disorders linked to hair lightening or graying include cystic fibrosis, celiac disease, hyperthy-roidism / hypothyroidism, vitiligo, alopecia areata, and genetic syndromes such as Werner syndrome, Louis-Bar syndrome, Waar-denburg syndrome, and Griscelli syndrome [2, 13, 17, 18 ].

[0013] The amino acid tyrosine, essential for catecholamine synthesis, and its hydroxylated product, DOPA (L-Dihydroxyphenylala-nine), serve as the starting points in the biosynthesis of melanin pigments. Melanin is synthesized through a series of enzyme-catalyzed reactions. The red-yellow melanin pigment, pheomelanin - a polymer soluble in alkaline solutions - is formed by the oxidative polymerization of cysteinyldopa, resulting from the condensation of the amino acid cysteine with dopaquinone. Eumelanin, an insoluble polymer that ranges in color from brown to black, is produced through the oxidative polymerization of 5, 6-dihydroxyindole. The hydroxylation of L-tyrosine to L-DOPA is catalyzed by tyrosinase (TYR) and a series of tyrosinase-related proteins

[0023] .

[0014] Tyrosinase, a type 3 membrane-bound protein

[0024] , is an essential enzyme in melanogenesis. It is localized within the membrane of melanosomes, the organelles specific to melanocytes. This enzyme is synthesized within the endoplasmic reticulum and then packaged in the Golgi apparatus before being transported to melanosomes - the site of melanin synthesis. Tyrosinase activity correlates directly with melanin production levels, and both melanosome formation and tyrosinase activity are stimulated by L-tyrosine

[0025] . The concentrations of L-tyro-sine and L-DOPA play a critical role in maintaining the homeostasis of the melanogenic system, with melanocytes orchestrating this regulatory balance

[0026] .

[0015] Azelaic acid is known to inhibit DNA synthesis and mitochondrial enzyme activity, impacting tyrosinase and reducing production of free radicals that contribute to skin hyperpigmentation

[0027] . Due to its direct cytotoxic effects on abnormal melanocytes, azelaic acid is beneficial in treating hyperpigmentation without affecting normal skin pigmentation or causing depigmentation.

[0016] In the human brain, neuromelanin is formed through the oxidation of dopamine to dopaquinone, a reaction catalyzed by tyrosinase. Excessive dopaquinone formation is associated with neural disorders and cell death

[0028] . Thus, tyrosinase is implicated in neurodegeneration related to Parkinson' s disease

[0029] and Huntington' s chorea [30, 31 ]. In addition to tyrosinase, two other proteins - dopachrome tautomerases - are involved in the conversion of tyrosine into melanin pigments. These proteins, designated as TRP-1 and TRP-2, are likewise located in melanosomes and are crucial for catalyzing the reactions that produce eumelanin. TRP-1 functions as a peroxidase and provides protection against oxidative stress [32, 33].

[0017] The onset of gray hair is associated with a reduction in melanocyte numbers, resulting from either defects in melanocyte stem cells or depletion of the follicular stem cell population [2-4, 19]. A common cause of follicular melanocyte death is oxidative stress, triggered by reactive oxygen species (ROS) production from hydrogen peroxide accumulation, a byproduct of the hair growth cycle, or ultraviolet (UV) radiation [2, 3, 19, 20]. Melanocytes naturally produce antioxidants - such as the apoptosis regulator BCL-2, catalase, and methionine sulfoxide reductase - to defend against ROS damage. However, these protective molecules are deficient in graying hair follicles [ 19, 20]. For instance, studies on BCL-2-def icient mice demonstrated graying by the second hair growth cycle [ 19, 20]. Interestingly, melanocytes in the outer root sheath are less susceptible to ROS damage and may serve as a pigment source for hair color restoration

[0019] . Environmental pollution, emotional stress, alcohol consumption, and smoking - factors that exacerbate oxidative stress - are also associated with premature graying [21, 22 ].

[0018] Anti-inflammatory agents are sometimes employed to counteract hair graying. While most cases reported are based on individual observations, the literature includes one prospective cohort study and a retrospective study involving 39 patients. Pavithran

[0034] documented that psoralen combined with UV light (PUVA therapy) induced repigmentation of gray hair, particularly in patients with premature graying. This concept originated from clinical experience with psoriasis treatment. Consequently, a prospective study was conducted on healthy patients aged 10-20 years with premature graying (n = 37 ). After 13 months of treatment, 46% of these patients exhibited complete scalp hair repigmentation with no recurrence over an 8-month follow-up period

[0035] . Seven additional patients showed partial repigmentation, either with pigment appearing at the proximal ends of gray hair shafts or with diffuse or patchy light-brown pigmentation

[0036] .

[0019] In a retrospective study involving men undergoing cisplatinbased chemotherapy for germ cell neoplasms, patients aged 15-54 years exhibited color changes in their regrown hair. Of the 69 patients, 16% reported darkening of hair color

[0037] . Two patients experienced sustained hair color restoration within 2 years post-chemotherapy.

[0020] Other isolated instances of anti-inflammatory agents inducing gray hair repigmentation have also been observed. Retinoic acid receptor activators, such as acitretin and etretinate, were linked to gray hair repigmentation in two patients with pityriasis rubra pilaris and one patient with psoriasis after 6-12 months of treatment [38-40]. In one case, a patient receiving interf eron-alpha for chronic hepatitis C reported scalp hair repigmentation, which began two months after treatment initiation and stabilized upon completion of therapy

[0041] . Case reports on other anti-inflammatory agents known to inhibit pro-inflammatory cytokines, including thalidomide, lenalidomide, adalimumab, cyclosporine, and prednisolone, also linked these drugs to hair repigmentation following 2-24 months of treatment [42-48 ]. Inflammatory processes within hair follicles can adversely affect hair pigmentation. However, the use of anti-inflammatory agents has not consistently led to hair repigmentation across all patients, indicating that multiple factors influence the graying process.

[0021] Stimulating melanogenesis presents an alternative approach for addressing gray hair. Five pharmacological agents believed to stimulate melanogenesis have been documented in one retrospective study and six case reports involving hair repigmentation. In a retrospective study, nine out of 133 patients receiving imatinib for chronic myelogenous leukemia exhibited repigmentation of gray hair within 2-14 months of treatment initiation

[0049] . Additionally, another tyrosine kinase inhibitor, erlotinib, was reported to induce progressive hair repigmentation in two separate cases of patients with metastatic lung adenocarcinoma within 3 months and 2 years, respectively, following treatment initiation [50-51 ]. In one case, hair repigmentation associated with erlotinib was observed after the resolution of scalp folliculitis

[0052] . However, erlotinib has also been associated with androgenic alopecia in certain cases, emerging months after treatment commencement

[0053] .

[0022] Color restoration was observed three years after initiating latanoprost eye drops for open-angle glaucoma

[0054] . Another patient reported hair repigmentation on the scalp 2.5 years after beginning tamoxifen therapy for breast cancer

[0055] .

[0023] Lastly, two patients taking levodopa for Parkinson' s disease noted diffuse hair repigmentation within 8-9 months of treatment initiation [56-57 ].

[0024] Vitamin and mineral deficiencies are considered among the causes of premature gray hair, thus replenishing such deficiencies may restore hair color. Research of B vitamins supplemented with calcium pantothenate or potassium para-amino-benzoic acid (PABA) represents some of the earliest targeted attempts at gray hair repigmentation. In two healthy patients, successful repigmentation of premature gray hair occurred with high-dose calcium pantothenate (200 mg per day), with initial repigmentation observed within one month of treatment

[0058] . A subsequent three-year prospective cohort study involving seven women aged 12-31 with premature gray hair reported repigmentation in two patients taking 200 mg per day for three months and in another two patients at a dose of 100 mg

[0059] . One prospective cohort study and one retrospective study investigated PABA' s effectiveness in treating gray hair [ 60, 61 ]. In 1941, Siev

[0062] conducted the first documented study of gray hair repigmentation using PABA at a dosage of 200 mg per day in 50 patients with premature or age-related graying. Subj ectively noted darkening of hair was observed in all patients after two months of treatment. Another study examined the effects of high-dose PABA ( 12-24 g / day) on age-related gray hair as part of systemic disease treatment for conditions such as cutaneous lymphoblastoma, dermatomyositis, herpetiform dermatitis, and scleroderma (n = 20)

[0063] . Seven patients reported hair darkening within 2-10 months of treatment. A prospective study assessing the combined administration of 100 mg calcium pantothenate and 200 mg PABA daily for gray hair treatment (involving 27 patients with age-related gray hair and 6 with premature gray hair) reported visually noticeable hair color change in two patients (both with age-related graying) and minor color change in seven after eight months of supplementation

[0064] . This study also noted that repigmented hair reverted to gray following supplementation cessation.

[0025] The market offers a range of active ingredients aimed at combating gray hair, with Greyverse being a notable example.

[0026] Greyverse is a water-glycerin solution containing synthetic palmitoyl tetrapeptide-20 amide, derived from a reaction between palmitic acid and synthetic tetrapeptide-20, which is composed of amino acid residues including arginine, histidine, phenylalanine, and tryptophan. Its efficacy is supported by extensive research, demonstrating a 66% increase in melanogenesis, a 30% reduction in hydrogen peroxide levels, a 5.3% decrease in the overall number of gray hairs, and a 30% reduction in their density after three months of application

[0065] . However, its use is limited by a high cost - $2000 per kilogram - and stability issues within formulations under varying pH levels and storage temperatures. In a 100 ml product formulation containing 2% Greyverse, the contribution to production cost is approximately $5. Research findings indicate no effect on hair growth stimulation, focusing solely on repigmentation.

[0027] Another product available on the market is Darkenyl. The active composition of Darkenyl includes water, glycerin, acetyl tyrosine, sodium meta-bisulfite, glycine, larch wood extract (Larix Europaea Wood Extract), zinc chloride, and camellia leaf extract (Camellia Sinensis Leaf Extract). The key active ingredients are synthetic acetyl tyrosine and natural larch extract (Larix Europaea Wood Extract). Darkenyl promotes the expression of genes associated with stem cell proliferation, hair follicle morphogenesis, and maintenance of the follicular stem cell phenotype. It increases cell proliferation by 30% compared to the positive control. Under oxidative stress conditions, the components significantly boost the expression of genes involved in antioxidant defense, hair renewal, and follicular pigmentation. Reactive oxygen species (ROS) accumulation decreases by 53%, and following oxidative stress exposure, Darkenyl restores the quantity of melanocytes and mela-noblasts in the hair follicle by 189%. Melanin production increases by 15% within three days of use. Clinical trials showed that after four months of treatment, Darkenyl reduced the amount of gray hair by an average of 17% compared to the placebo group

[0066] . Despite its promising results, Darkenyl has limitations, including a high cost - ranging from $50 (se- rum) to $150 (shampoo) - and the presence of synthetic ingredients, which may deter consumers who prefer natural components. While Darkenyl is free from side effects and drug interactions, its tyrosine content may interact with medications for Parkinson' s disease, hypertension, or depression. These conditions are often prevalent in the age group where graying may start, thereby restricting Darkenyl ' s use for certain consumers who would otherwise be within its target demographic.

[0028] 2, 3, 5, 4 ' -Tetrahydroxystilbene 2-O-β-D-Glucoside (THSG) is an active compound derived from the traditional Chinese medicinal plant Polygonum multiflorum Thunb. Pharmacological studies have demonstrated THSG' s extensive biological functions in treating conditions such as atherosclerosis, lipid metabolism disorders, vascular and cardiac remodeling, vascular fibrosis, cerebrovascular ischemia, learning and memory impairment, neuroinflammation, Alzheimer ' s and Parkinson' s diseases, diabetic complications, hair growth issues, among various other conditions. Research

[0067] indicates that THSG induces activation of MITF (Melanocyte Inducing Transcription Factor) and also promotes phosphorylation of CREB (Cyclic AMP Response Element Binding Protein), which binds and activates MITF. Additionally, the activation of p38 MAPK (Mitogen-Activated Protein Kinase) has been shown to play a crucial role in THSG-induced melanogenesis in B16F1 cells by upregulating MITF and tyrosinase expression. Consequently, the pigmentation-enhancing properties of THSG may serve as an adjunct therapy in addressing conditions associated with graying hair. Gray hair management presents a multifaceted challenge, necessitating a comprehensive approach targeting the stimulation of melanogenesis, mitigation of oxidative stress effects, and potentially supplying essential melanin synthesis components. THSG distinguishes itself from other gray hair treatment actives on the market by combining both antioxidant and melanogenesis-stimulating properties along with a natural origin. In contrast, most commercially available actives are synthetic and offer a narrow range of effects, which often increases the number of active ingredients required in formulations. However, a key limitation of THSG is its stability. Data

[0067] indicates that its half-life at 25°C is 47.57 days at pH 1.5 and only 0.11 days at pH 9.9, presenting formulation challenges.

[0029] THSG is also occasionally found within Polygonum multiflorum root extract, which is included in dietary supplements and hair care products. This root has been traditionally used in Chinese medicine for treating and preventing various health conditions. However, its use is limited by potential hepatotoxicity, as various studies have documented its adverse effects on liver health. Cases of abdominal pain, diarrhea, nausea, and vomiting have been reported, linked to anthraquinones like emodin present in the extract

[0068] . Emodin inhibits cell proliferation and is cytotoxic to human reproductive tissues

[0069] . Utilizing a single purified component of the extract allows targeted action on the desired effect with increased efficacy, as the substance is isolated from other compounds, thereby eliminating unwanted side effects.

[0030] Copper deficiency in the body is associated with hypopigmentation of hair. Copper is included in popular dietary supplements aimed at preventing gray hair and restoring hair color, such as Not today, Grey and Gray Escape™ Advanced Anti-Gray Hair Growth Supplement. An ex vivo study

[0070] confirmed that a copper tripeptide, composed of a positively charged copper ion and the amino acid residues L-alanyl-L-histidyl-L-lysine Cu, promotes the growth of human hair follicles. This growth-promoting effect is hypothesized to arise from the stimulation of cell proliferation and prevention of apoptosis in dermal papilla cells. Oxidative stress can adversely affect hair, including contributing to the onset of gray hair. Researchers

[0071] confirmed, using one method, that copper ions adsorbed onto hair from tap water increase hair damage induced by sunlight exposure, particularly through the increased loss of protein during shampooing. However, another method did not show similar effects. Due to the lack of conclusive evidence on the influence of copper compounds on oxidative stress, it is not possible to definitively assert a positive impact of this active ingredient in combating gray hair. The use of copper peptides as an anti-gray hair agent is also described in patent KR20120048830A

[0072] . However, there is limited research on the efficacy of copper peptides when applied topically to the hair and scalp, and no experimental evidence to confirm their role in melanogenesis stimulation.

[0031] The inventors hypothesized that the combined application of THSG and Copper Compounds may support the induction of melanogenesis, provide antioxidant protection, and reduce dandruff. However, this hypothesis is limited by the instability of THSG at varying temperatures and pH levels, as previously noted, the potential oxidative activity of copper ions, and the lack of evidence supporting the melanogenesis-stimulating properties of Copper Compounds when applied topically to the hair and scalp.

[0032] With regard to the prior art CN 107 427 437 A, which can be considered as the closest prior art to the present invention as defined in the claims, the following should be noted:

[0033] Said document discloses the use of our component A, i. e.

[0034] 2, 3, 5, 4 '-Tetrahydroxystilbene 2-O-β-D-glucoside (referred to subsequently as "THSG"), preferably in combination with a phenolic compound different from THSG, applied to the hair and / or scalp for preventing and treating hair greying, see paragraph

[0001] of said document. Said further phenolic compound is described in paragraph

[0047] of said document. In paragraphs

[0017] -

[0018] of said document, it has been described that said THSG protects melanocytes from oxidative stress and is therefore more effective than currently available products in preventing and / or treating greyed-out hair. The data in Example 1 of said document show that human melanocytes treated with the compositions of said document (extract A: 19.1 wt. % THSG + 21.9 wt. % phenolic compound; extract B: 15.9 wt. % THSG + 10.2 wt. % phenolic compound; extract C: 4.3 wt. % THSG + 7.2 wt. % phenolic compound) and subsequently subj ected to oxidative stress are more viable then the control DMSO and N-ace-tyl-cysteine. In the ESR' s written opinion of the present application' s priority application EP 24 216 436. 6 it has been noted that the provision of an alternative combination to that of said prior art document for the same purpose, i. e. hair graying, is not inventive as " the application provides no scientific evidence that the antioxidant effect of the claimed composition against vitamin C renders credible that the claimed composition is effective against hair greying". However, this is wrong. The application provides scientific evidence data showing the antioxidant effect of the claimed composition " THSG + copper compound" normalized to the known an-tioxidative vitamin C, along with the (also normalized to vitamin C) data for the copper compounds and THSG alone, as shown in Table 4 of Example 3. As noted below said Table 4, " Tn this study, THSG, Copper Tripeptide and Copper Bisglycinate were evaluated for their antioxidant capacities against Ascorbic acid (100%). Notably, THSG emerged as the standout, exhibiting the highest antioxidant capacity at 37.31 % relative to Vitamin C. This highlights its potential as a superior antioxidant. In combination with Copper Tripeptide, there is synergy resulting in an antioxidant activity enhanced by 30. 96% relative to the activity of solo THSG. Thus, the use of combination of THSG and Copper Tripeptide looks promising for use as an anti-grey hair product, as it solves the oxidative stress issue." Therefore, contrary to the opinion in the priority applications ESR and based on said data, it has been shown that the claimed composition " THSG + copper compound" is effective against hair greying via its antioxidative action, which is over-additive if compared to the data for the copper compounds and THSG alone. This over-additive, i. e. synergistic, effect cannot be ignored.

[0035] Second, in view of the written opinion in the ESR, where it has been further noted " Moreover, as no data regarding the effect of the copper compounds (alone) on melanin production is provided, it cannot be evaluated whether the combination of THSG and a copper compound is synergistic, additional data as per Example 4b of the present application have been added, clearly showing the synergistic over-additive effect on melanin production of the claimed components.

[0036] Said over-additive synergistic data of Example 3 and Example 4a and 4b provide for the surprising technical effects which cannot be derived from the prior art disclosing THSG (e. g. US 2012 / 0164242 Al, CN 107 427 437 A, CN 101 606 988 A) or a copper compound (CN 104 257 564 A, CN 114 712 259 A, US 2022 / 0151912 A1, CN 105 055 203 A, CA 2 632 542 ), but not a combination of both.

[0037] INVESTIGATIONS

[0038] Example 1. In-silico investigation THSG affinity to MC1R protein

[0039] 1.1 Materials and methods

[0040] 1.1.1 Investigated ingredients Table 1. Investigated ingredients in-silico study

[0041] No. Ingredient

[0042] 1 2, 3, 5, 4 ' - Tetrahydroxystilbene 2-O-B-D-Glucoside

[0043] 2 Copper Tripeptide

[0044] 3 Copper Bisglycinate

[0045]

[0046] 1.2 Investigation

[0047] The MC1R gene and its encoded receptor protein for melanocytestimulating hormone (MSH) are primarily associated with the activation of eumelanin pigment biosynthesis in response to UV radiation. In addition, the MC1R gene is able to regulate the work of other genes associated with melanogenesis. MC1R protein structure was sourced in. cif format from the Cambridge Crystallographic Data Centre. For further computational analysis, the MC1R structure was converted and saved in.xyz format. The ligand structures were obtained from PubChem

[0073] .

[0048] 1.2.1 Molecular Modeling and Affinity Analysis for Lig- and-MClR Interaction

[0049] For the computational studies, a personal computer equipped with an Intel Core i9-13900K CPU operating at 2.3 GHz and 64 GB of RAM was employed. The operating system used was Windows 11, 64-bit. The structural optimization of both MC1R and the ligands was performed using ORCA 5.0.3 software

[0074] . Subsequently, the ligand-MClR complexes were manually assembled, and the resulting models were stored in.xyz format for further analysis using ORCA 5.0.3 software

[0074] . The following quantum chemical approximations were applied in the calculations: the density functional theory (DFT) functional used was PBE0

[0075] , with dispersion corrections applied via D3 (BJ)

[0076] . Solvation effects were considered using the conductor-like polarizable continuum model (CPCM), with water as the solvent. The basis set utilized was def2-TZVPP

[0077] . Geometry optimizations were conducted to achieve stable species, including both the reagents and the resulting complexes.

[0050] 1. 3 Results

[0051] THSG was selected as the primary agent for the study. This substance has an estimated affinity score -7, 5 kcal / mol (Figure 1 ), indicating a strong interaction.

[0052] Copper tripeptide has an estimated affinity score -5, 6 kcal / mol (Figure 2 ), Copper Bisglycinate has an estimated affinity score -4, 3 kcal / mol (Figure 3). These metrics indicate a strong interaction between Copper Compounds and MC1R.

[0053] Conclusion: The affinity of THSG and Copper compounds with MC1R protein, confirmed using artificial intelligence, shows a potential to enhance melanin production. These findings suggest that THSG and Copper Compound could be a focus for future research, with a view to confirm in-vitro these properties.

[0054] Example 2. In-vitro cytotoxicity study of the investigated compounds: THSG and Copper Tripeptide, and market benchmark Greyverse

[0055] 2.1 Materials and methods

[0056] 2.1.1 Investigated ingredients Table 2. Investigated ingredients

[0057] No. Ingredient

[0058] 1 2, 3, 5, 4 ' - Tetrahydroxystilbene 2- O-p-D-Glucoside

[0059] 2 Copper Tripeptide

[0060] 3 Greyverse

[0061]

[0062] 2.2 Investigation

[0063] Human melanocytes were seeded in 75 cm2flasks (Corning, USA), cultured in a specific culture medium, and expanded in an incubator at 37 °C in the presence of 5% CO2. Upon reaching con-fluency, the cells were seeded in 6-well plates (Corning, USA) for subsequent quantification of the proposed mediator.

[0064] 2.2.1 Evaluation of non-cytotoxic concentrations of THSG and Greyverse by MTT in melanocyte culture

[0065] Cell viability was determined by a colorimetric method using MTT dye (Sigma Chemical, St. Louis, Mo. ). To perform the test, the products were prepared in culture medium and applied to a 96-well plate in a serial dilution in the range of 100 to 0.03 mg / mL using a dilution factor of 3.168. Human melanocytes were seeded in 75 cm2flasks (Corning, USA), cultured in a specific culture medium, and expanded in an incubator at 37 °C in the presence of 5% CO2. Upon reaching confluency, the cells were seeded in 96- and 6-well plates (Corning, USA) for the determination of non-cytotoxic concentrations of the evaluated products. The melanocytes culture was incubated for a period of 48 hours. MTT was then added to the culture at a concentra- tion of 0.5 mg / ml ( 100 pl / well) and incubated for an additional 4 hours. The contents of the well were removed and 100 pL of isopropanol was added to solubilize the formazan crystals formed. The absorbance of each well was determined at 570 nm on a Multiskan GO monochromator (Thermo Scientific, Finland). Cell viability was expressed as a percentage and calculated according to the equation:

[0066] Absorbance of cells incubated with the product

[0067] % Cell viability = - - - — -: - —— - Control absorbance x 100

[0068] 2.2.2 Evaluation of non-cytotoxic concentrations of Copper Tripeptide and Copper Bisglucinate by MTT in fibroblast culture

[0069] Cytotoxicity of substances was assessed using cell lines of non-immortalised fibroblasts in the MTT metabolic test. This method is based on the reduction reaction of the yellow te-trazolium salt (MTT) by mitochondrial dehydrogenases of living cells to purple formazan crystals, which are insoluble in aqueous medium.

[0070] For the assay, cells were cultured in DMEM medium supplemented with 20% fetal calf serum, L-glutamine and 1% penicil-lin / streptomycin in an atmosphere of 5% CO2at 37 °C until mono-layer formation. To perform the test, 1000÷3000 cells in 200 microlitres of culture medium are added to the wells of a 96-well plate depending on the proliferative potential. Cells are thoroughly suspended before introduction into the plate. The cell suspension was introduced into the wells of the plate using a multichannel pipette and sterile tips. The plates with cells were then incubated for 24 hours in a CO2incubator for cell adhesion to the substrate. Using a multichannel pipette and sterile tips, aliquots of prepared solutions of compounds at the tested concentrations were added to the wells of the plate with cells. After addition of the test substances, the cells were cultured in a CO2incubator under standard conditions for 48 hours. At the end of the incubation time, the culture medium with the test substances was removed from the plate. A mixture was prepared in a multi-channel pipetting tub: 9 ml of culture medium + 1 ml of MTT reagent (5 mg / ml in Hanks ' solution) per 96-well plate. The prepared reaction mixture was added in a volume of 100 pl into each well of the plate and incubated in a CO2incubator for 3.5 hours.

[0071] At the end of the incubation time, the culture medium with the tested compounds was removed, 100 pl of DMSO was added and incubated for 5-10 minutes. The resulting violet staining was detected at a wavelength of 550 nm on a Tecan infinite 200 Pro micro-plate reader (Switzerland).

[0072] The ability of Copper Tripeptide to exert cytotoxic effect on cells was also evaluated by microscopy with counting the area of viable cells in the programme 'BCAn-alyzer ’ on fibroblast cell lines.

[0073] 2. 3 Results

[0074] The cytotoxicity of THSG and Greyverse against non-immortal-ised melanocyte cell line was investigated at a concentration range of 0.032% to 100%. Figures 4 and 5 illustrate the residual metabolic activity of the cells in the presence of the tested compound as a result of the MTT assay.

[0075] As seen in Figure 4, the evaluated product GREYVERSE PRODUCT CODE: 3383301-S50ML showed non-cytotoxic concentrations when starting the dilution of 10.00 mg / mL.

[0076] The cytotoxicity of Copper Tripeptide against non-immortalised fibroblast cell line was investigated at a concentration range of 0. 6% to 5%. Figure 6 illustrates the residual metabolic activity of the cells in the presence of the tested compound as a result of the MTT assay. For fibroblasts, the IC50for Copper Tripeptide was significantly found to be 28.78%. The value was obtained by extrapolation method.

[0077] Figures 7 and 8 show visual differences in the effects of the actives on melanocytes after 48h incubation.

[0078] Conclusion: The results of non-cytotoxic concentration studies conducted on melanocyte and fibroblast cell lines identify a range of component performance that does not harm or reduce the efficiency of melanin production (due to reduced cell counts). Thus, the non-cytotoxic concentrations of THSG and Copper Compounds are 0 to 0.2% and 0 to 1%, respectively. Non-cytotoxic concentrations of Greyvers are 0 to 1%.

[0079] Example 3. Determination of antioxidant activity towards ascorbic acid for a liquid sample using the Ferric reducing antioxidant power (FRAP)

[0080] 3.1 Materials and methods

[0081] 3.1.1 Investigated ingredients

[0082] Table 3. Investigated ingredients in the FRAP assay

[0083] No. Ingredient

[0084] 1 2, 3, 5, 4 ' - Tetrahydroxystilbene 2-O-p-D-Glucoside

[0085] 2 Copper Tripeptide

[0086] 3 Copper Bisglycinate

[0087]

[0088] For the experiment, 0.16% (w / v) aqueous solutions of water-soluble THSG, 0.005% (w / v) aqueous solutions of water-soluble Copper Tripeptide and 0.1% (w / v) aqueous solutions of water-soluble Copper Bisglucinate were prepared. Each compound, weighing 0.16 g, was dissolved in 100 mL of distilled or deionized water, with the aid of a magnetic stirrer to ensure complete dissolution.

[0089] 3.2 Investigation

[0090] The FRAP assay was conducted in alignment with a modified version of the protocol originally delineated by Benzie and Strain ( 1996). All utilized reagents were of analytical grade and procured from recognized suppliers to ensure the assay' s consistency and reliability. A 300 mM acetate buffer at pH 3. 6 was prepared by dissolving 3.1 g of sodium acetate trihydrate (Sigma-Aldrich, St. Louis, MO, USA) in 16 mL of glacial acetic acid (Fisher Scientific, Hampton, NH, USA), with the volume adjusted to 1 L using distilled water. The TPTZ (2, 4, 6-tri-pyridyl-s-triazine ) solution was made at 10 mM concentration in 40 mM HC1, and a 20 mM solution of FeCl3- 6H2O was also prepared, both sourced from Sigma-Aldrich (St. Louis, MO, USA). For the preparation of the FRAP reagent, acetate buffer, TPTZ solution, and FeCl3- 6H2O solution were combined in a 10: 1: 1 (v / v / v) ratio. This mixture was subsequently warmed to 37 °C in a water bath (Julabo SW23, Julabo GmbH, Seelbach, Germany) immediately prior to the assay to ensure the reaction proceeded under optimal conditions. In the assay, 150 pL of the FRAP reagent was dispensed into each well of a 96-well plate, to which 50 pL of either the prepared sample or ascorbic acid standard was added. The components were thoroughly mixed using a vortex mixer (Vortex-Genie 2, Scientific Industries, Bohemia, NY, USA) to ensure uniformity.

[0091] The reaction mixtures were then incubated at 37 °C for 30 minutes in a dark environment, allowing the reduction reactions to complete. Post incubation, the absorbance of each mixture was determined at 593 nm using a spectrophotometer (Shimadzu UV-1800, Shimadzu Corporation, Kyoto, Japan).

[0092] Absorbance values obtained from blank samples were subtracted from all other readings to correct for any baseline absorbance. The antioxidant capacities of the samples were quantified by comparing their absorbance values to those of an ascorbic acid standard curve, which was plotted under identical conditions.

[0093] This procedure was meticulously outlined to detail the execution of the FRAP assay, ensuring the reproducibility and reliability of the measurements of antioxidant capacities in the analyzed samples.

[0094] The general formula used to calculate the antioxidant capacity of the samples in the assay is as follows:

[0095] (Absorbance of Standart — Absorbance of Blank)

[0096] Antioxidant Capacity = — - - - - - - - - - - - — — — - x Concentration of Standart (Assorbance of Sample — Absorbance of Blank)

[0097] Absorbance of Sample is the measured absorbance of the reaction mixture containing the test sample. Absorbance of Blank is the absorbance of the reaction mixture containing all reagents except the sample or standard (negative control). Absorbance of Standard is the measured absorbance of the reaction mixture containing a known concentration of the standard antioxidant (ascorbic acid). Concentration of Standard is the known concentration of ascorbic acid used in the assay.

[0098] 3.3 Result Table 4. Results of the Antioxidant Capacity for investigated ingredients

[0099] Ingredient Antioxidant Capacity (Relative to Vitamin C), %

[0100] 2, 3, 5, 4 ' - Tetrahy37.31 (p < 0.05) droxystilbene 2-O-B-D- Glucoside ( 0.16%)

[0101] Copper Tripeptide -0.40 (p < 0.05) ( 0. 005%)

[0102] Copper Bisglucinate 1.24 (p < 0.05)

[0103] ( 0.1%)

[0104] 2, 3, 5, 4 ' - Tetrahy48.86 (p < 0.05) droxystilbene 2-O-B-D- Glucoside ( 0.16%) + Copper Tripeptide ( 0.005%)

[0105] 2, 3, 5, 4 ' - Tetrahy43.21 (p < 0.05) droxystilbene 2-O-B-D- Glucoside ( 0.16%) + Copper Bisglycinate ( 0.1%)

[0106]

[0107] In this study, THSG, Copper Tripeptide and Copper Bisglycinate were evaluated for their antioxidant capacities against Ascorbic acid ( 100%). Notably, THSG emerged as the standout, exhibiting the highest antioxidant capacity at 37.31% relative to Vitamin C. This highlights its potential as a superior antioxidant. In combination with Copper Tripeptide, there is a syn-ergy resulting in an antioxidant activity enhanced by 30.96% relative to the activity of solo THSG. Thus, the use of combination of THSG and Copper Tripeptide looks promising for use as an anti-grey hair product, as it solves the oxidative stress issue. Example 4a. Study of the effect of THSG, Copper Tripeptide, Copper Bisglycinate, GREYVERSE on melanin production in human melanocyte culture

[0108] 4.1 Materials and methods

[0109] 4.1.1 Investigated ingredients

[0110] Table 5. Investigated ingredients in-silico study

[0111] No. Ingredient

[0112] 1 2, 3, 5, 4 ' - Tetrahydroxystilbene 2-O-B-D-Glucoside

[0113] 2 Copper Tripeptide

[0114] 3 Copper Bisglycinate

[0115] 4 Greyverse

[0116]

[0117] 4.2 Investigation

[0118] Human melanocytes were seeded in 75 cm2flasks (Corning, USA), cultured in a specific culture medium, and expanded in an incubator at 37 °C in the presence of 5% CO2. Upon reaching con- fluency, the cells were seeded in 6-well plates (Corning, USA) for subsequent quantification of the proposed mediator.

[0119] 4.2.1 Evaluation of the effects of THSG and Greyverse on melanin production

[0120] Evaluation of the preclinical effects of three previously determined non-cytotoxic concentrations of the evaluated product GREYVERSE PRODUCT CODE: 3383301-S50ML and 2, 3, 5, 4 ’ - tetrahydroxystilbene 2-0-B-D-glucoside, on melanin production in culture of human melanocytes. Melanin concentration was measured in a 405 nm spectrophotometer in the cell lysate of melanocyte cultures and compared based on a curve with concentrations of 500.00-1.95 pg / mL melanin (Sigma).

[0121] The statistical evaluation used the ANOVA test to measure the variation of the results, comparing the data between the groups. The Bonferroni posttest was then applied, which strengthened and made the result presented in the ANOVA more precise. The 5% significance level was used.

[0122] 4.2.2 Evaluation of the effects of THSG alone and in combination with Copper Compound Copper Tripeptide on melanin production

[0123] The cell cultures were incubated with 3 non-cytotoxic concentrations of the evaluated product Copper Compounds added with 0.13% of the evaluated product 2, 3, 5, 4 ' - tetrahydroxystilbene 2-O-β-D-glucoside CAS No: 82373-94-2. The concentrations of the evaluated product Copper Compounds were 0.01, 0.005 and 0.001 mg / ml. For quantifications of melanin synthesis, human melanocytes were treated with the products for 48 hours.

[0124] Melanin concentration was measured in a 405 nm spectrophotometer in the cell lysate of melanocyte cultures and compared based on a curve with concentrations of 500.00-1.95 pg / mL melanin (Sigma).

[0125] The statistical evaluation used the ANOVA test to measure the variation of the results, comparing the data between the groups. The Bonferroni posttest was then applied, which strengthened and made the result presented in the ANOVA more precise. The 5% significance level was used.

[0126] 4. 3 Results Table 6. Percentage increase in melanin production when using Greyverse

[0127] No. Concentration, % Increase in melanin production, %

[0128] 1 2. 0 28. 54

[0129] 2 1. 0 24.23

[0130] 3 0. 5 21.44

[0131]

[0132] Table 7. Percentage increase in melanin production when using 2, 3, 5, 4 ' - tetrahydroxystilbene 2-0- p-D-glucoside

[0133] No. Concentration, % Increase in melanin production, %

[0134] 1 0. 3 31. 67

[0135] 2 0.2 24. 59

[0136] 3 0. 1 22. 90

[0137]

[0138] Table 8. Percentage increase in melanin production when using 0.13% 2, 3, 5, 4 ' - tetrahydroxystilbene 2-0- p-D-glucoside and Copper Compound Copper Tripeptide

[0139] No. Concentration of Copper ComIncrease in melanin propound Copper Tripeptide, % duction, %

[0140] 1 0. 01 36.19

[0141] 2 0. 005 30.06

[0142] 3 0. 001 25.15

[0143]

[0144] Figure 9 represents the total melanin production obtained in the melanocyte cultures treated with Greyverse. Figure 10 represents the total melanin production obtained in the melanocyte cultures treated with 2, 3, 5, 4 ' - tetrahydroxystilbene 2-0- p-D-glucoside. Figure 11 represents the total melanin production obtained in the melanocyte cultures treated with the evaluated products Copper Compounds and 2, 3, 5, 4 ' - tetrahydroxystilbene 2-0- p-D-glucoside. Culture ' s treatment demonstrated a significant modulation on melanin synthesis in

[0145] 36. 19% (p<0. 01 ), 30. 06% (p<0. 05) and 25. 15% (p<0. 05), respectively, at the evaluated concentrations 0.01, 0.005 and 0.001 mg / ml of the evaluated product Copper Compound added with 0.13% of 2, 3, 5, 4 ' - tetrahydroxystilbene 2-O-β-D-glucoside each, in relation to the basal control.

[0146] The results obtained allow us to infer that the evaluated product Copper Compound added with 0.13% of the evaluated product 2, 3, 5, 4 ' - tetrahydroxystilbene 2-O-β-D-glucoside increases the synthesis of melanin, therefore, we can infer that the evaluated products Copper Compound and 2, 3, 5, 4 ' - tetrahydroxystilbene 2-O-β-D-glucoside product have pigmentation activity.

[0147] Water-soluble copper compounds can serve as effective copper sources. These compounds include, but are not limited to, copper tripeptide, copper bisglycinate, copper lysinate / pro-linate, Saccharomyces copper enzyme, copper picolinate, copper glycinate, copper aspartate, and copper gluconate.

[0148] Supplementary Example 4b. Evaluation of the melanin production effects of

[0149] - THSG alone ( 0.3%, 0.2%, 0.1%), and

[0150] compounds comprising copper, namely

[0151] - Copper Tripeptide alone ( 0.01%, 0.005%, 0.001%), and

[0152] - Copper Bisglycinate alone ( 0.001. %, 0.005%, 0.001%), as well as combinations thereof, namely

[0153] - THSG ( 0.1%) and Copper Tripeptide ( 0. 01%, 0.005%, 0.001%), - THSG ( 0.2%) and Copper Tripeptide ( 0. 01%, 0.005%, 0.001%), - THSG ( 0.1%) and Copper Bisglycinate ( 0.01%, 0.005%, 0.001%), - THSG ( 0.2%) and Copper Bisglycinate ( 0.01%, 0.005%, 0.001%).

[0154] The tests, measuring and statistical evaluation have been car-led out as indicated for Example 4a above.

[0155] Figure 14 illustrates the data below for the total melanin content measured in melanocyte cultures following treatment with the test product, Copper Tripeptide alone.

[0156] Table 9. Percentage increase in melanin production when using Copper Tripeptide alone

[0157] No. Concentration, mg / ml Increase in melanin production, %

[0158] 1 0. 01 19.92

[0159] 2 0. 005 17.56

[0160] 3 0. 001 11. 14

[0161]

[0162] The treatment resulted in a statistically significant, dosedependent stimulation of melanogenesis. Specifically, at concentrations of 0.01, 0.005, and 0.001 mg / ml, the Copper Tripeptide formulation increased melanin production by 19.92% (P < 0.01 ), 17.56% (P < 0.05), and 11.14% (P < 0.05), respectively, relative to the basal control.

[0163] Figure 15 illustrates the data below for the total melanin production in melanocyte cultures treated with Copper Bisglu-cinate alone. Table 10. Percentage increase in melanin production when using Copper Bisglucinate alone

[0164] No. Concentration, mg / ml Increase in melanin production, %

[0165] 1 0. 01 18.23

[0166] 2 0. 005 14. 02

[0167] 3 0. 001 7. 68

[0168]

[0169] As can be seen from said data, exposure to the test compound Copper Bisglucinate alone resulted in a statistically significant, concentration-dependent stimulation of melanin synthesis. The observed increases were 18.23% (P < 0.01 ), 14.02% (P < 0.05), and 7. 68% (P < 0.05) at concentrations of 0.01, 0.005, and 0.001 mg / ml, respectively, when compared to the ba-sal control group.

[0170] Figure 16 illustrates the data below for the total melanin production in melanocyte cultures treated with the evaluated formulations containing Copper Tripeptide in combination with 2, 3, 5, 4 ' -tetrahydroxystilbene 2-O-β-D-glucoside (THSG).

[0171] Table 11. Percentage increase in melanin production when using Copper Tripeptide and 2, 3, 5, 4 ' - tetrahydroxystilbene 2-O-B-D-glucoside

[0172] No. Concentration of Copper Increase in melanin production, % Tripeptide, mg / ml

[0173] 0.1% 2, 3, 5, 4 ' - tetrahydroxystilbene 2-O-B-D-glucoside

[0174] 1 0. 01 31.18

[0175] 2 0. 005 23. 72

[0176]

[0177] 3 0. 001 20. 14

[0178] 0.2% 2, 3, 5, 4 ' - tetrahydroxystilbene 2-O-B-D-glucoside

[0179] 1 0. 01 39.01

[0180] 2 0. 005 32.88

[0181] 3 0. 001 29.53

[0182]

[0183] As can be seen from said data, the combined treatment produced a statistically significant and concentration-dependent stimulation of melanogenesis. More specifically, at a fixed concentration of 0.1% THSG, the addition of Copper Tripeptide at 0.01, 0.005, and 0.001 mg / ml increased melanin synthesis by 31.18% (P < 0.01 ), 23.72% (P < 0.05), and 20.14% (P < 0.05), respectively, relative to the basal control. Furthermore, when combined with a higher concentration of 0.2% THSG, Copper Tripeptide at the same respective concentrations ( 0.01, 0.005, and 0.001 mg / ml) elicited an even more pronounced stimulatory effect, enhancing melanin production by 39.01% (P < 0.01 ), 32.88% (P < 0.05), and 29.53% (P < 0.05). These results indicate a synergistic interaction between Copper Tripeptide and THSG in promoting melanin synthesis.

[0184] Figure 17 illustrates the data below for the total melanin production in melanocyte cultures following treatment with combined formulations of Copper Bisglucinate and 2, 3, 5, 4 ' -tetrahydroxystilbene 2-O-β-D-glucoside (THSG). Table 12. Percentage increase in melanin production when using Copper Bisglucinate and 2, 3, 5, 4 ' - tetrahydroxystilbene 2-0-B-D-glucoside

[0185] No. Concentration of Copper Increase in melanin production, % Bisglucinate, mg / ml

[0186] 0.1% 2, 3, 5, 4 ' - tetrahydroxystilbene 2-O-B-D-glucoside

[0187] 1 0. 01 29.00

[0188] 2 0. 005 26.39

[0189] 3 0. 001 25.72

[0190] 0.2% 2, 3, 5, 4 ' - tetrahydroxystilbene 2-O-B-D-glucoside

[0191] 1 0. 01 31. 33

[0192] 2 0. 005 30. 58

[0193] 3 0. 001 25. 69

[0194]

[0195] As can be seen from said data, the combinatorial treatments produced statistically significant enhancement of melanogenesis across all tested concentrations. More specifically, when supplemented with 0.1% THSG, Copper Bisglucinate at concentrations of 0.01, 0.005, and 0.001 mg / ml elevated melanin synthe-sis by 29.00% (P < 0.01 ), 26.39% (P < 0.05), and 25.72% (P < 0.05), respectively, compared to basal control levels. Furthermore, at the higher THSG concentration of 0.2%, the same graded concentrations of Copper Bisglucinate ( 0.01, 0.005, and 0.001 mg / ml) further increased melanin production by 31.33% (P < 0.01 ), 30.58% (P < 0.05), and 25. 69% (P < 0.05), demonstrating a clear dose-response relationship for the combination therapy. Example 5. Evaluation of antiseptic efficacy using the time kill test for Malassezia furfur

[0196] 5.1 Materials and methods

[0197] 5.1.2 Investigated ingredients

[0198] Table 13. Investigated ingredients

[0199] No. Ingredient

[0200] 1 2, 3, 5, 4 ' - Tetrahydroxystilbene 2- O-B-D-Glucoside

[0201]

[0202] 5.2 Investigation

[0203] The microorganism Malassezia furfur (ATCC 14521 ) was inoculated into the investigational product. Consecutive subcultures of Malassezia furfur (ATCC 14521 ) were grown in specific broth and incubated at 30°C for 24 hours. The third subculture was quantified according to Pharmacopoeial parameters ( 106 CFU / mL). After determining the microbial load, the microorganisms were inoculated on the product evaluated. The inoculum was diluted at the ratio of 1: 100 for the test. For this test, the investigational product 2, 3, 5, 4 ' - Tetrahydroxystilbene 2-O- β-D-Glucoside was diluted in sterile deionized water at 0.13%.

[0204] The suspension of the microorganism was inoculated into the sample. Aliquots of the suspension were collected after 30 seconds, 1 minute and 3 minutes of contact. They were then neutralized and diluted in 0.1% peptone water, then plated on the appropriate culture medium. Incubation was carried out for 72 hours at 30°C. At the end of this period, the colonies present were evaluated and measured.

[0205] The evaluated product was subj ected to a sanitizing activity investigation using the linear regression method. To determine the lethality profile (log CFU / mL vs. time), the ability of the product to reduce, on a logarithmic scale, the standardized microbial populations after 30 seconds, 1 minute and 3 minutes of contact was verified.

[0206] 5.3 Results

[0207] Table 14. Results obtained with group 1 - 2, 3, 5, 4 ' - Tetrahydroxystilbene 2-O-p-D-Glucoside - 0, 13% at the corresponding contact times

[0208] Evaluated microMalassezia furfur (ATCC 14521 ) organism

[0209] Initial populaContact time

[0210] tion

[0211] 30 seconds 1 minute 3 minutes

[0212] 2.0xl04(CFU / mL) 2. 4xl041. 4xl046. 0x103(CFU / mL) (CFU / mL) (CFU / mL)

[0213] Logarithmic 0. 0 0. 15 0. 52 Reduction

[0214] Percentage of 0. 00% 30. 00% 70. 00% microbial

[0215] reduction

[0216]

[0217] The products 2, 3, 5, 4 ' - Tetrahydroxystilbene 2-O-p-D-Glucoside showed antimicrobial and antiseptic activity. Specifically for the strain Malassezia furfur (ATCC 14521 ), it produced a 70% reduction after 3 minutes of contact with the microorganism. Example 6. Stability studies of components at different temperatures

[0218] 6.1 Materials and methods

[0219] 6.1.1 Investigated solution

[0220] Table 15. Investigated solution

[0221] Compounds Concentration

[0222] 2, 3, 5, 4 ' - Tetrahy0. 1%

[0223] droxystilbene 2-O-B- D-Glucoside

[0224]

[0225] The solution was prepared in distilled water. The pH was adjusted to 6.5. The solutions were stored for stability evaluation under the following conditions: at 40°C, 25°C, 4 °C.

[0226] The solutions were stored for 40 days, then solutions which were kept at 40°C and 25°C were sent for component composition study.

[0227] 6.2 Investigation

[0228] Stability results after 40 days were evaluated for the following parameters: pH, appearance, and color.

[0229] The analysis to determine the composition was carried out by ultra-performance liquid chromatography / MS on a Waters Acquity UPLC chromatograph with diode matrix UV detector and TQD tandem quadrupole MC detector (Waters).

[0230] Mobile phase A (MP A). Water-acetonitrile ( 95: 5) mixture with formic acid.

[0231] Mobile phase B (MP B). Acetonitrile with formic acid. The test solutions were chromatographed under the following conditions:

[0232] - 2 μl sample volume;

[0233] - 0.21 x 5.0 cm Acquity UPLC BEH C18 column (1.7 μm);

[0234] - column temperature 35°C;

[0235] - flow rate 0.5 ml / min;

[0236] - gradient chromatography mode is formed by mixing mobile phases A and B according to the scheme in the Table 16.

[0237] Table 16. Scheme for mixing the mobile phases

[0238] Time, min MP A, % MP B, %

[0239] 0 100 0

[0240] 4. 0 0 100

[0241] 4. 1 100 0

[0242] 4. 0 100 0

[0243]

[0244] UV detection: 220-500 nm.

[0245] MS conditions:

[0246] 1 ) MS detection in negative ion mode:

[0247] - detector parameters: capillary voltage - 3 kV; cone voltage - 31 V; capillary temperature 450 0C; source temperature 120 0C; drying gas flow rate 800 1 / h, cone gas flow rate 50 1 / h and scanning in the mass range from 80 to 1000 units; 2 ) MS detection in positive ion mode:

[0248] - detector parameters: capillary voltage - 3 kV; cone voltage - 50 V; capillary temperature 450 0C; source temperature 120 0C; drying gas flow rate 800 1 / h, gas flow rate in the cone 50 1 / h and scanning in the mass range from 80 to 1000 units.

[0249] 6.3 Results

[0250] The appearance of the solutions after 40 days is shown in Figure 12. Table 17 summarizes the results of the analysis of these solutions.

[0251] Table 17. Stability results

[0252] Temperature pH Color Appearance of

[0253] stor- age, 0 14 40 0 days 14 40 0 14 40 °C days days days days days days days days

[0254] 40 6.31 6.55 light light

[0255] brown brown

[0256] 6.7 Trans- homogeneous clear 25 6. 65 6. 64 parent light yellow liquid yellow

[0257] 4 6. 67 6. 63 very light

[0258] light yellow

[0259] yellow

[0260]

[0261] Solutions that were stored at temperatures of 40°C and 25°C darkened. We carried out a component study to identify what this was due to. The following chromatograms at 280 nm of samples No. 1 (25°C) and No. 2 (40°C) were obtained by component analysis. The results are shown in Figure 13.

[0262] The results demonstrate that after degradation at 40°C, new components were formed, and the concentration of previously detected components changed. The values are presented in Table 18.

[0263] Table 18. Ratio of concentration and availability of components in solutions stored at 40°C and 25°C.

[0264] Name Peak Area (280 nm) Change in concentration of components in relation to sam40°C 25°C

[0265] ple No. 1

[0266] p-Hydroxybenzaldehyde 1.18 3.9E+08 63646368 +612.20%

[0267] 2,3,5,4' - Tetrahydroxystilbene 2-O-β-D-Glucoside 1.34 3.83E+08 1.76E+09 -21.74%

[0268] 2-O-p-D-Glucoside

[0269]

[0270] At 40°C, the concentration of 2, 3, 5, 4 ' -Tetrahydroxystilbene 2-O-glucoside decreases by a factor of 0.22, while the concentration of p-Hydroxybenzaldehyde increases by a factor of 6.12. The observed increase in the color intensity of the solution is attributed to the formation of various oligomeric degradation products that absorb light in the visible spectrum.

[0271] Based on the findings of this study, it can be concluded that the application of 2, 3, 5, 4 ' -Tetrahydroxystilbene 2-O-p-D-Glu-coside is restricted to a temperature range not exceeding 25°C, as degradation of the molecule begins at higher temperatures. The following embodiments are of particular interest:

[0272] 1. A composition comprising the following components A and B:

[0273] A) 2, 3, 5, 4 '-Tetrahydroxystilbene 2-O-β-D-glucoside, preferably less than 0.2% by weight of said composition, and B) at least one compound comprising copper, preferably less than 1% by weight of said composition.

[0274] 2. The composition of embodiment 1, wherein said component B is selected from the group consisting of copper tripeptide, copper bisglycinate, copper lysinate and / or prolinate, Sac- charomyces copper enzyme, copper picolinate, copper glycinate, copper aspartate, and copper gluconate, or any combination thereof.

[0275] 3. The composition of embodiment 2, wherein said component B is copper bisglycinate alone or in combination with copper tripeptide.

[0276] 4. The composition of embodiment 2, wherein said component B is copper tripeptide alone or in combination with copper bisglycinate.

[0277] 5. The composition of any of embodiments 2-4, wherein said copper tripeptide comprises a positively charged copper ion and amino acid residues L-alanyl-L-histidyl-L-lysine.

[0278] 6. The composition of any of the preceding embodiments, wherein said composition is assembled as single composition comprising said components A and B, or as a kit-of-parts composition separating said components A and B into separate entities, and wherein said separated entity parts of said kit-of-parts are for combining said components A and B prior use.

[0279] 7. The composition of any of the preceding embodiments, wherein said composition is formulated for application on a subject's hair and / or scalp.

[0280] 8. The composition of any of the preceding c embodiments, wherein said composition is a formulation selected from the following: liquid, aerosol, suspension, solution, tincture, cream, paste, lotion, ointment, gel, balsam, foam, shampoo.

[0281] 9. The composition of any of the preceding embodiments, wherein said composition is for preventing and / or reversing hair greying and / or dandruff in a subj ect, wherein said subj ect is preferably a human or an animal.

[0282] 10. Use of the composition of any of the preceding embodiments in the non-medical treatment of the scalp and or hair of a subj ect, including cosmetic, aesthetic and dermatological non-medical treatment.

[0283] 11. The use of embodiment 10, wherein said non-medical treatment prevents and / or reverses hair greying and / or dandruff in a subj ect, wherein said subj ect is preferably a human or animal.

[0284] 12. The composition of any of c embodiments 1-8 for use as a medicament.

[0285] 13. The composition for use of embodiment 12, wherein said medicament is selected from the group consisting of an antiseptic, antimicrobial and antioxidant.

[0286] 14. The composition of any of embodiments 1-8 for use in the treatment of a disease selected from the group consisting of premature graying of hair (PGH), achromotrichia, canities and hypomelanosis.

[0287] 15. The use of 2, 3, 5, 4 '-Tetrahydroxystilbene 2-O-β-D-glucoside in combination with at least one compound comprising copper in the manufacture of composition of any of embodiments 1- 7. REFERENCES

[0288] 1. Panhard S, Lozano I, Loussouarn G. Greying of the human hair: a worldwide survey, revisiting the ' 50 ' rule of thumb. Br J Dermatol. 2012 Oct; 167 ( 4 ): 865-73.

[0289] 2. Park AM, Khan S, Rawnsley J. Hair Biology: growth and Pigmentation. Facial Plast Surg Clin North Am. 2018 Nov; 26 ( 4 ): 415-24.

[0290] 3. Kumar AB, Shamim H, Nagaraj u U. Premature Graying of Hair: review with Updates. Int J Trichology. 2018 Sep-Oct; 10 ( 5 ): 198-203.

[0291] 4. Tobin D. ( 2010 ). The Aging Hair Pigmentary Unit. In: R.

[0292] Trueb and D. Tobin, ed., Aging Hair, 1 st ed. Verlag Berlin Heidelberg: Springer, pp. 77- 89

[0293] 5. Tobin DJ, Paus R. Graying: gerontobiology of the hair follicle pigmentary unit. Exp Gerontol. 2001 Jan; 36 ( 1 ): 29-54.

[0294] 6. Jo S J, Paik SH, Choi JW, Lee JH, Cho S, Kim KH, et al Hair graying pattern depends on gender, onset age and smoking habits. Acta Derm Venereol. 2012 Mar; 92 ( 2 ): 160-l.

[0295] 7. Sato S, Jitsukawa K, Sato H, Yoshino M, Seta S, Ito S, et al Segmented heterochromia in black scalp hair associated with iron-deficiency anemia. Canities segmentata sideropaenica.

[0296] Arch Dermatol. 1989 Apr; 125 ( 4 ): 531-5.

[0297] 8. Noppakun N, Swasdikul D. Reversible hyperpigmentation of skin and nails with white hair due to vitamin B12 deficiency. Arch Dermatol. 1986 Aug; 122 ( 8 ): 896-9. 9. Acer E, Kaya Erdogan H, Igrek A, Parlak H, Saracoglu Z, Bilgin M. Relationship between diet, atopy, family history, and premature hair graying. J Cosmet Dermatol. 2018. [ PubMed] 1473-2130

[0298] 10. Tobin DJ. The cell biology of human hair follicle pigmentation. Pigment Cell Melanoma Res. 2011 Feb; 24 ( 1 ): 75-88.

[0299] 11. Stenn KS, Paus R. Controls of hair follicle cycling. Physiol Rev. 2001 Jan; 81 ( 1 ): 449-94

[0300] 12. FitzpatrickTB, Brunet P, Kukita A. The nature of hair pigment. In: Montagna W, Ellis RA, editors. The Biology of Hair Growth. New York: Academic Press; 1958. pp. 255-303

[0301] 13. Cline DJ. Changes in hair color. Dermatol Clin.

[0302] 1988 Apr; 6 ( 2 ): 295-303.

[0303] 14. ShaffraliFC, McDonagh AJ, MessengerAG. Hair darkening in porphyria cutanea tarda. Br J Dermatol. 2002 Feb; 146 ( 2 ): 325-9.

[0304] 15. Pinkus H. Postinflammatory hair darkening. Arch Dermatol. 1960 Aug; 82 ( 2 ): 263-4

[0305] 16. Verbov J. Erosive candidiasis of the scalp, followed by the reappearance of black hair after 40 years. Br J Dermatol.

[0306] 1981 Nov; 105 ( 5 ): 595-8.

[0307] 17. Dalgic B, Egritas O. Gray hair and acrodermatitis entero-pathica-like dermatitis: an unexpected presentation of cystic fibrosis. Eur J Pediatr. 2011 Oct; 170 ( 10 ): 1305-8 18. Redondo P, Guzman M, Marquina M, Pretel M, Aguado L, Lloret P, et al [Repigmentation of gray hair after thyroid hormone treatment ]. Actas Dermosifiliogr. 2007 Nov; 98 ( 9 ): 603-10

[0308] 19. Seiberg M. Age-induced hair greying - the multiple effects of oxidative stress. Int J Cosmet Sci. 2013 Dec; 35 ( 6 ): 532-8.

[0309] 20. Wood JM, Decker H, Hartmann H, Chavan B, Rokos H, Spencer JD, et al Senile hair graying: H2O2-mediated oxidative stress affects human hair color by blunting methionine sulfoxide repair. FASEB J. 2009 Jul; 23 ( 7 ): 2065-75.

[0310] 21. Akin Belli A, Etgu F, Ozbas Gok S, Kara B, Dogan G. Risk Factors for Premature Hair Graying in Young Turkish Adults. Pedi-atr Dermatol. 2016 Jul; 33 ( 4 ): 438-42.

[0311] 22. Trueb RM. Association between smoking and hair loss: another opportunity for health education against smoking? Dermatology. 2003; 206 ( 3 ): 189-91.

[0312] 23. Niu C, Aisa HA. Upregulation of melanogenesis and tyrosinase activity: Potential agents for vitiligo. Molecules.

[0313] 2017; 22: 1303-1305.

[0314] 24. Rzepka Z, Buszman E, Beberok A, Wrzesniok D. From tyrosine to melanin: Signaling pathways and factors regulating melanogenesis. Postepy Hig Med Dosw. 2016; 70: 695-708.

[0315] 25. D ' I schia M, Wakamatsu K, Napolitano A, Briganti S, Garcia-Borron JC, Kovacs D, Meredith P, Pezzella A, Picardo M, Sarna T, et al. Melanins and melanogenesis: Methods, standards, protocols. Pigment Cell Melanoma Res. 2013; 26: 616- 633. 26. Slominski A, Zmijewski MA, Pawelek J. L-tyrosine and L-di-hydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment Cell Melanoma Res. 2012; 25: 14-27.

[0316] 27. Pillaiyar T, Manickam M, Namasivayam V. Skin whitening agents: Medicinal chemistry perspective of tyrosinase inhibitors. J Enzyme Inhib Med Chem. 2017; 32: 403-425.

[0317] 28. Hollinger JC, Angra K, Halder RM. Are natural ingredients ef fective in the management of hyperpigmentation? A systematic review. J Clin Aesthet Dermatol. 2018; 11: 28-37.

[0318] 29. Pillaiyar T, Manickam M, Namasivayam V. Skin whitening agents: Medicinal chemistry perspective of tyrosinase inhibitors. J Enzyme Inhib Med Chem. 2017; 32: 403-425.

[0319] 30. Caruntu C, Boda D, Constantin C, Caruntu A, Neagu M. Catecholamines increase in vitro proli feration of murine B16F10 melanoma cells. Acta Endocrinol ( Copenh) 2014; 10: 545-558.

[0320] 31. Diaconeasa A, Boda D, Solovan C, Enescu DM, Vilcea AM, Zurac S. Histopathologic features of Spitzoid lesions in di fferent age groups. Rom J Morphol Embryol. 2013; 54: 51- 62.

[0321] 32. Hasegawa T. Tyrosinase-expressing neuronal cell line as in vitro model of Parkinson ' s disease. Int J Mol Sci.

[0322] 2010; 11: 1082-1089. doi: 10.3390 / ijms11031082.

[0323] 33. Zurac S, Neagu M, Constantin C, Cioplea M, Nedelcu R, Bastian A, Popp C, Nichita L, Andrei R, Tebeica T, et al. Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors. Oncol Lett. 2016; 11: 3354-3360.

[0324] 34. Pavithran K. Puvasol Therapy in Premature Greying of Hair. Indian J Dermatol Venereol Leprol. 1986 Mar-Apr; 52 ( 2 ): 74-5. 35. Robinson A, Jones W. Changes in scalp hair after cancer chemotherapy. Eur J Cancer Clin Oncol. 1989 Jan; 25 ( 1 ): 155- 6.

[0325] 36. Ward RD, Miller HL, Shipman AR. A case of repigmentation and curling of hair on acitretin therapy. Clin Exp Dermatol.

[0326] 2014 Jan; 39 ( 1 ): 91-2.

[0327] 37. Seckin D, Yildi z A. Repigmentation and curling of hair after acitretin therapy. Australas J Dermatol. 2009 Aug; 50 ( 3 ): 214- 6.

[0328] 38. Vesper JL, Fenske NA. Hair darkening and new growth associated with etretinate therapy. J Am Acad Dermatol. 1996 May; 34 ( 5 Pt 1 ): 860.

[0329] 39. Kavak A, Akcan Y, Korkmaz U. Hair repigmentation in a hepatitis C patient treated with interferon and ribavirin. Dermatology. 2005; 211 ( 2 ): 171-2.

[0330] 40. Babu KG, Rasheshyam D, Lalitha N. Canities— reversal with chemotherapy. J Assoc Physicians India.

[0331] 1995 Aug; 43 ( 8 ): 577. [ PubMed] 0004-5772

[0332] 41. Lovering S, Miao W, Bailie T, Amato D. Hair repigmentation associated with thalidomide use for the treatment of multiple myeloma. BMJ Case Rep. 2016 Jul; 2016: bcr2016215521.

[0333] 42. TintleSJ, Dabade TS, Kalish RA, Rosmarin DM. Repigmentation of hair following adalimumab therapy. Dermatol Online J.

[0334] 2015 Jun; 21 ( 6 ): 13030 / qt 6fn0tlxz. [ PubMed] 1087-2108

[0335] 43. Dasanu CA, Mitsis D, Alexandrescu DT. Hair repigmentation associated with the use of lenalidomide: graying may not be an irreversible process! J Oncol Pharm Pract. 2013 Jun; 19 ( 2 ): 165-9. 44. KhaledA, TrojjetsS, Zeglaoui F, Fazaa B, KamounMR. Repigmentation of the white hair after systemic corticosteroids for bullous pemphigoid. J Eur Acad Dermatol Venereol.

[0336] 2008 Aug; 22 ( 8 ): 1018-20

[0337] 45. Sadighha A, Zahed GM. Hair darkening after treatment with cyclosporin in a patient with psoriasis. J Eur Acad Dermatol Venereol. 2008 Nov; 22 ( 10 ): 1239-41.

[0338] 46. Rebora A, Delmonte S, Parodi A. Cyclosporin A-induced hair darkening. Int J Dermatol. 1999 Mar; 38 ( 3 ): 229-30.

[0339] 47. Etienne G, Cony-Makhoul P, MahonFX. Imatinib mesylate and gray hair. N Engl J Med. 2002 Aug; 347 ( 6 ): 446.

[0340] 48. Cheng YP, Chen HJ, Chiu HC, Chen H. Erlotinib-induced hair repigmentation. Int J Dermatol. 2014 Jan; 53 ( 1 ): e55-7.

[0341] 49. Alexandrescu DT, KauffmanCL, Dasanu CA. Persistent hair growth during treatment with the EGFR inhibitor erlotinib.

[0342] Dermatol Online J. 2009 Mar; 15 ( 3 ): 4

[0343] 50. Bellandi S, Amato L, Cipollini EM, Antiga E, Brandini L, Fab-bri P. Repigmentation of hair after latanoprost therapy. J Eur Acad Dermatol Venereol. 2011 Dec; 25 ( 12 ): 1485-7.

[0344] 51. Hampson JP, DonnellyA, Lewis- Jones MS, Pye JK. Tamoxi fen-induced hair colour change. Br J Dermatol. 1995 Mar; 132 ( 3 ): 483-4.

[0345] 52. Reynolds NJ, Crossley J, Ferguson I, Peachey RD. Darkening of white hair in Parkinson' s disease. Clin Exp Dermatol.

[0346] 1989 Jul; 14 ( 4 ): 317-8. 53. Dizdar O. et al. Adjuvant use of epidermal growth factor receptor kinase inhibitors may prevent bone metastases in patients with non-small cell lung carcinoma / / Journal of Thoracic Oncology. - 2007. - T. 2. - No. 12. - C. 1136.

[0347] 54. Grainger KM. Pigmentation in Parkinson' s disease treated with levodopa. Lancet. 1973 Jan; 1 ( 7794 ): 97-8.

[0348] 55. Pasricha J. Success ful treatment of gray hairs wtih high dose calcium pantothenate. Indian J Dermatol Venereol Leprol.

[0349] 1981; 47 ( 6 ): 311-3. 0378- 6323

[0350] 56. Pasricha JS. Ef fect of Grey Hair Evulsion on the response to calcium pantothenate in premature grey hairs. Indian J Dermatol Venereol Leprol. 1986 Mar-Apr; 52 ( 2 ): 77-80. [ PubMed] 0973-3922

[0351] 57. Sieve B. Clinical Achromotrichia. Science ( 80- )

[0352] 1941; 94 ( 2437 ): 257-258

[0353] 58. ZarafonetisCJ. Darkening of gray hair during para-amino-benzoic acid therapy. J Invest Dermatol. 1950 Dec; 15 ( 6 ): 399-401.

[0354] 59. Brandaleone H, Main E, Steele J. The ef fect of calcium pantothenate and para-aminobenzoic acid on gray hair. Exp Biol Med. 1943; 53 ( 1 ): 47-9.

[0355] 60. Philip M, Samson JF, Simi PS. Clofazimine-induced Hair Pigmentation. Int J Trichology. 2012 Jul; 4 ( 3 ): 174-5.

[0356] 61. Read GM. Verapamil and hair colour change. Lancet.

[0357] 1991 Dec; 338 ( 8781 ): 1520. 62. Drug Information. UpToDate. www.uptodate. com. Published 2019.

[0358] 63. Christoph T, Müller-RöverS, Audring H, Tobin DJ, Hermes B, Cotsarelis G, et al The human hair follicle immune system: cellular composition and immune privilege. Br J Dermatol.

[0359] 2000 May; 142 (5): 862-73.

[0360] 64. Bs YM, Diehl J, Levins PC. Promising alternative clinical uses of prostaglandin F2α analogs: beyond the eyelashes. J Am Dermatology. 2015; 72 (4 ): 712-6.

[0361] 65. Chavan D. Reversal of Premature Hair Graying Treated with a Topical Formulation Containing a-Melanocyte-Stimulating Hormone Agonist (Greyverse Solution 2%) / / International Journal of Trichology. - 2022. - T. 14. - No. 6. - C. 207-209.

[0362] 66. Patent W02020089216A1. Hair care active agent. URL: https: / / patents. google. com / patent / WO2020089216A1 / en

[0363] 67. Zequn Jiang, Jimin Xu, Minghai Long, Zhiming Tu, Guangxiao Yang, Guangyuan He. 2, 3, 5, 4 ' -tetrahydroxystilbene-2-O-β-D-glucoside (THSG) induces melanogenesis in B16 cells by MAP kinase activation and tyrosinase upregulation. Life Sciences 85 (2009) 345-350.

[0364] 68. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [ Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Polygonum Multiflorum. [Updated 2020 Aug 18 ]. Available from: https: / / www. ncbi.nlm.nih.gov / books / NBK548795 /

[0365] 69. Dong X, Fu J, Yin X, Cao S, Li X, Lin L; Huyiligeqi; Ni J. Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics. Phytother Res. 2016 Aug; 30 ( 8 ): 1207-18. doi: 10. 1002 / ptr. 5631. Epub 2016 May 18. PMID: 27188216; PMCID: PMC7168079.

[0366] 70. Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The ef fect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007 Jul; 30 ( 7 ): 834- 9. doi: 10. 1007 / BF02978833. PMID: 17703734

[0367] 71. Millington KR, Marsh JM. UV damage to hair and the ef fect of antioxidants and metal chelators. Int J Cosmet Sci. 2020 Apr; 42 ( 2 ): 174- 184. doi: 10. 1111 / ics. 12601. Epub 2020 Mar 11. PMID: 31955440

[0368] 72. Patent KR20120048830A. A method for preparing the treatment with tripeptide derivatives for prematurely gray hair. URL: https: / / patents. google. com / patent / KR20120048830A / en

[0369] 73. Kim S C. J., Cheng T, Gindulyte A, He J, He S, Li Q, Shoemaker BA, Thiessen PA, Yu B, Zaslavsky L, Zhang J, Bolton EE. PubChem 2023 update. / / Nucleic Acids Res.. 2023. V. 6. No.

[0370] 51(D1). P. 1373.

[0371] 74. Neese F. Software update: The ORCA program system— Version 5. 0 / / WIREs Computational Molecular Science. 2022. V. 12. No. 5. P. e1606.

[0372] 75. Adamo C., Barone V. Toward reliable density functional methods without adj ustable parameters: The PBE0 model / / The Journal of Chemical Physics. 1999. V. 110. No. 13. P. 6158.

[0373] 76. Grimme S., Ehrlich S., Goerigk L. Ef fect of the damping function in dispersion corrected density functional theory / / Journal of Computational Chemistry. 2011. V. 32. No. 7. P.

[0374] 1456. 77. Weigend F., Ahlrichs R. Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: Design and assessment of accuracy / / Physical Chemistry Chemical Physics. 2005. V. 7. No. 18. P. 3297.

Claims

CLAIMS1. A composition comprising the following components A and B:A) 2, 3, 5, 4 '-Tetrahydroxystilbene 2-O-β-D-glucoside not more than 0.3% by weight of said composition, preferably not more than 0.2% by weight of said composition, preferably in the range of 0.05% to 0.2%, further preferably in the range selected from the following: 0.05% - 0.18%, 0.10% - 0.18%, 0.10% - 0.15%; andB) at least one compound comprising copper less than 1% by weight of said composition, preferably in the range of 0.001% to less than 1%, further preferably in the range selected from the following: 0.001% to 0.80% or to 0.01%, 0.005% - 0.50%, 0.01% - 0.10%.

2. The composition of claim 1, wherein said component B is selected from the group consisting of copper tripeptide, copper bisglycinate, copper lysinate and / or prolinate, Saccha- romyces copper enzyme, copper picolinate, copper glycinate, copper aspartate, and copper gluconate, or any combination thereof.

3. The composition of claim 2, wherein said component B is copper bisglycinate alone or in combination with copper tripeptide.

4. The composition of claim 2, wherein said component B is copper tripeptide alone or in combination with copper bisglycinate.

5. The composition of any of claims 2-4, wherein said copper tripeptide comprises a positively charged copper ion and amino acid residues L-alanyl-L-histidyl-L-lysine.

6. The composition of any of the preceding claims, wherein said composition is assembled as single composition comprising said components A and B, or as a kit-of-parts composition separating said components A and B into separate entities, and wherein said separated entity parts of said kit-of-parts are for combining said components A and B prior use.

7. The composition of any of the preceding claims, wherein said composition is formulated for application on a subject's hair and / or scalp.

8. The composition of any of the preceding claims, wherein said composition is a formulation selected from the following: liquid, aerosol, suspension, solution, tincture, cream, paste, lotion, ointment, gel, balsam, foam, shampoo.

9. Use of the composition of any of the preceding claims for preventing and / or reversing at least one of the following in a subject: hair greying, including premature graying of hair (PGH), achromotrichia, canities, hypomelanosis.

10. The use of claim 9, wherein said subject is a human or animal.

11. The composition of any of claims 1-8 for use as a medicament.

12. The composition for use of claim 11, wherein said medicament is selected from the group consisting of an antiseptic, antimicrobial and antioxidant.

13. The composition of any of claims 1-8 for use in the treatment of dandruff in a subject.

14. The use of 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside in combination with at least one compound comprising copper in the manufacture of composition of any of claims 1-8.

Images